公开(公告)号：US20180362542A1

公开(公告)日：2018-12-20

申请号：US16062680

申请日：2016-12-14

Applicant: Novartis AG

Inventor： Robert John AVERSA ,  Matthew T. BURGER ,  Michael Patrick DILLON ,  Thomas A. DINEEN, Jr. ,  Rajesh KARKI ,  Savrithi RAMURTHY ,  Vivek RAUNIYAR ,  Richard ROBINSON ,  Patrick James SARVER

IPC: C07D498/04 ,  C07D491/044 ,  C07D487/04 ,  A61P35/00

CPC classification number: C07D498/04 ,  A61P35/00 ,  C07D487/04 ,  C07D491/04 ,  C07D491/044

Abstract: The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers.

公开(公告)号：US20200002330A1

公开(公告)日：2020-01-02

申请号：US16309076

申请日：2017-06-12

Applicant: NOVARTIS AG

Inventor： Zhuoliang CHEN ,  Jorge Garcia FORTANET ,  Rajesh KARKI ,  Matthew J. LAMARCHE ,  Dyuti MAJUMDAR ,  Lawrence Blas PEREZ ,  Martin SENDZIK ,  Troy Douglas SMITH ,  Fan YANG ,  Bing YU

IPC: C07D471/04 ,  C07D513/04 ,  C07D495/04 ,  C07D487/04 ,  C07D403/14 ,  C07D519/00 ,  C07D455/02 ,  C07D401/14

Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, R1, R2 and R3 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

公开(公告)号：US20240199609A1

公开(公告)日：2024-06-20

申请号：US18523565

申请日：2023-11-29

Applicant: NOVARTIS AG

Inventor： Zhuoliang CHEN ,  Jorge Garcia FORTANET ,  Rajesh KARKI ,  Matthew J. LAMARCHE ,  Dyuti MAJUMDAR ,  Lawrence Blas PEREZ ,  Martin SENDZIK ,  Troy Douglas SMITH ,  Fan YANG ,  Bing YU

IPC: C07D471/04 ,  C07D401/14 ,  C07D403/14 ,  C07D455/02 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D401/14 ,  C07D403/14 ,  C07D455/02 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04 ,  C07D519/00

Abstract: The present invention relates to compounds of formula I:






in which Y1, Y2, R1, R2 and R3 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

公开(公告)号：US20240336598A1

公开(公告)日：2024-10-10

申请号：US18589841

申请日：2024-02-28

Applicant: Novartis AG

Inventor： Daniela ANGST ,  Philippe Bolduc ,  Matthew William Carson ,  Atwood Kim CHEUNG ,  Véronique Darsigny ,  Xiang GAO ,  Viktor HORNAK ,  Keith JENDZA ,  Rajesh KARKI ,  Ajay Kumar LAL ,  Gang LIU ,  Justin Yik Ching MAO ,  Jeffrey M. McKENNA ,  Erik MEREDITH ,  Muneto MOGI ,  Vivek RAUNIYAR ,  Liansheng SU ,  Ritesh TICHKULE ,  Shuangxi WANG ,  Chun ZHANG ,  Liang ZHAO ,  Rui ZHENG

IPC: C07D403/14 ,  A61K31/517 ,  A61K31/55 ,  A61K45/06 ,  C07D239/95 ,  C07D401/12 ,  C07D401/14

CPC classification number: C07D403/14 ,  A61K31/517 ,  A61K31/55 ,  A61K45/06 ,  C07D239/95 ,  C07D401/12 ,  C07D401/14

Abstract: The disclosure relates to a compound of Formula (I):




or a pharmaceutically acceptable salt thereof wherein A, Ra to Rd, and R4 to R7, are as described herein, as well as compositions and methods of using such compounds.

公开(公告)号：US20210300919A1

公开(公告)日：2021-09-30

申请号：US17130374

申请日：2020-12-22

Applicant: Novartis AG

Inventor： Zhuoliang CHEN ,  Jorge Garcia FORTANET ,  Rajesh KARKI ,  Matthew J. LAMARCHE ,  Dyuti MAJUMDAR ,  Lawrence Blas PEREZ ,  Martin SENDZIK ,  Troy Douglas SMITH ,  Fan YANG ,  Bing YU

IPC: C07D471/04 ,  C07D513/04 ,  C07D495/04 ,  C07D487/04 ,  C07D401/14 ,  C07D519/00 ,  C07D455/02 ,  C07D403/14 ,  A61P35/00

Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, R1, R2 and R3 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.